Active Implants’ VENUS Clinical Trial for Persistent Knee Pain Now Underway in Memphis

Active Implants’ VENUS Clinical Trial for Persistent Knee Pain Now Underway in Memphis

OrthoMemphis Only Site in the South – and One of 10 Sites Nationwide – Enrolling Patients
in New Study of Investigational NUsurface® Meniscus Replacement


MEMPHIS, Tennessee – February 9, 2016 – Active Implants, a Memphis-based company that develops orthopedic implant solutions, today announced that the company’s VENUS (Verification of the Effectiveness of the NUsurface® System) trial is now underway at OrthoMemphis. OrthoMemphis is the only center in the South – and just one of 10 sites nationwide – participating in the VENUS clinical trial to evaluate the Active Implants’ NUsurface (pronounced “new surface”) investigational meniscus implant for the treatment of persistent knee pain caused by injured or deteriorating meniscus cartilage.


The meniscus is a tissue pad between the thigh and shin bones. Once damaged, the meniscus has a very limited ability to heal.  Over 1 million partial meniscectomies to remove or repair a torn meniscus are performed in the U.S. every year, about the same as the total number of hip and knee replacement surgeries combined. However, many patients still experience persistent knee pain following meniscus surgery. NUsurface is being evaluated as a new treatment option to fill the gap between minimally invasive meniscus repair and total knee replacement.


“There aren’t many options for patients who experience persistent knee pain following meniscus surgery,” said Dr. Randall Holcomb, orthopedic surgeon at OrthoMemphis. “Damage to the meniscus can lead to arthritis and the need for knee replacement surgery. We hope this study finds that the NUsurface implant alleviates pain in these patients, as well as helps them delay or avoid knee replacement surgery.”


The VENUS study will enroll approximately 130 patients at orthopedic centers in the U.S., Europe and Israel. Participants who meet study requirements and agree to enter the trial are randomized to receive either the NUsurface device or non-surgical treatment, which is the current standard of care for patients with persistent knee pain following meniscus surgery.


“We are excited to have OrthoMemphis – a leader in orthopedic care throughout the Southern states that is conveniently located in our back yard – participating in the VENUS study,” said Henry Klyce, chief executive officer of Active Implants, which established its U.S. headquarters in Memphis in 2004. “There is a large, unmet need in the orthopedic market for a new treatment option for the many patients who continue to suffer from knee pain even after undergoing meniscus surgery.”


To be eligible for the study, participants must be between the ages of 30 and 75 and have pain after medial meniscus surgery that was performed at least six months ago. To learn more about the study, visit or call (844) 680-8951 or visit



About the NUsurface® Meniscus Implant

In the U.S., the NUsurface® Meniscus Implant, from Active Implants LLC, is an investigational treatment for patients with persistent knee pain following medial meniscus surgery.  NUsurface is made from medical grade plastic and, as a result of its unique materials, composite structure and design, does not require fixation to bone or soft tissue. The NUsurface device mimics the function of the natural meniscus and redistributes loads transmitted across the knee joint.  It is inserted into the knee joint through a small incision, and patients typically can go home soon after the operation.  After surgery, patients undergo a six-week rehabilitation program. NUsurface has been used clinically in Europe since 2008 and Israel since 2012.


About Active Implants LLC

Active Implants LLC develops orthopedic implant solutions that complement the natural biomechanics of the musculoskeletal system, allowing patients to maintain or return to an active lifestyle.   Active Implants is privately held with headquarters in Memphis, Tennessee.  European offices are in Driebergen, The Netherlands, with R&D facilities in Netanya, Israel. For more information, visit


About OrthoMemphis

OrthoMemphis’ team of 19 doctors provides surgical and non-surgical treatment in general orthopedic and subspecialty areas of sports medicine, spine, hand, foot & ankle, hip & knee, total joint replacement, treatments of bone and soft tumors of the extremities (benign and malignant) in children and adults, and workers’ compensation injuries. For more information, go to


CAUTION Investigational device. Limited by United States law to investigational use.


« Back on the Saddle | Health + Fitness Magazine